Precision BioSciences (NASDAQ:DTIL) Issues Earnings Results, Misses Estimates By $0.46 EPS

Precision BioSciences (NASDAQ:DTIL) announced its quarterly earnings results on Thursday. The company reported ($1.26) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.46), FiscalAI reports. Precision BioSciences had a negative net margin of 96.73% and a negative return on equity of 67.70%.

Precision BioSciences Stock Up 0.9%

Shares of DTIL stock traded up $0.07 during mid-day trading on Friday, reaching $7.49. 240,103 shares of the company were exchanged, compared to its average volume of 341,234. Precision BioSciences has a fifty-two week low of $3.53 and a fifty-two week high of $9.62. The company has a debt-to-equity ratio of 0.29, a quick ratio of 14.02 and a current ratio of 14.02. The company has a market capitalization of $193.24 million, a P/E ratio of -2.67 and a beta of 1.27. The business’s 50 day simple moving average is $7.36 and its 200 day simple moving average is $6.33.

Hedge Funds Weigh In On Precision BioSciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Bleichroeder LP boosted its holdings in shares of Precision BioSciences by 54.7% during the fourth quarter. Bleichroeder LP now owns 1,662,500 shares of the company’s stock valued at $6,916,000 after acquiring an additional 587,500 shares during the period. Boothbay Fund Management LLC increased its holdings in shares of Precision BioSciences by 497.1% in the 4th quarter. Boothbay Fund Management LLC now owns 1,066,050 shares of the company’s stock worth $4,435,000 after acquiring an additional 887,515 shares during the period. Lynx1 Capital Management LP increased its holdings in shares of Precision BioSciences by 0.6% in the 3rd quarter. Lynx1 Capital Management LP now owns 1,042,596 shares of the company’s stock worth $5,755,000 after acquiring an additional 6,545 shares during the period. Alyeska Investment Group L.P. bought a new stake in Precision BioSciences in the 4th quarter valued at about $3,320,000. Finally, Vanguard Group Inc. lifted its position in Precision BioSciences by 21.5% in the 3rd quarter. Vanguard Group Inc. now owns 492,596 shares of the company’s stock valued at $2,719,000 after purchasing an additional 87,242 shares during the last quarter. 37.99% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have commented on DTIL. HC Wainwright reissued a “buy” rating on shares of Precision BioSciences in a report on Monday, August 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Precision BioSciences in a report on Wednesday. Oppenheimer initiated coverage on shares of Precision BioSciences in a research note on Tuesday, June 9th. They issued an “outperform” rating and a $20.00 price objective for the company. JonesTrading reissued a “buy” rating and set a $30.00 price objective on shares of Precision BioSciences in a report on Friday, April 17th. Finally, Wall Street Zen lowered shares of Precision BioSciences from a “hold” rating to a “sell” rating in a research report on Saturday. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $32.25.

About Precision BioSciences

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.